Innovative Cell Therapy FibroBiologics specializes in cell therapy using fibroblasts to regenerate tissue and treat chronic diseases, positioning them as leaders in advanced medical solutions. This unique approach opens avenues for partnerships with healthcare providers seeking cutting-edge treatments.
Diversified Clinical Pathways With 150+ patents in clinical pathways like Disc Degeneration, Multiple Sclerosis, and Cancer, FibroBiologics offers a diverse range of solutions. This breadth of applications presents opportunities for collaborations with medical research institutions looking to expand their treatment portfolio.
Tech-Savvy Operations Utilizing a tech stack including NitroPack, Squarespace, and Google Tag Manager, FibroBiologics demonstrates a commitment to leveraging technology for efficient operations. This tech proficiency can attract partnerships with tech-focused companies seeking to enhance their digital presence and operations.
Steady Growth Trajectory Despite being in the revenue range of $0-10M, FibroBiologics recent funding of $5M reflects a growth trajectory. This financial stability can appeal to investors and potential partners looking to collaborate with a company poised for expansion and success.
Competitive Landscape Analysis Compared to industry giants like Roche, Johnson & Johnson, and Pfizer, FibroBiologics may present a more agile and focused partnership option. Leveraging their size advantage and innovative solutions, FibroBiologics can cater to partners seeking a dynamic and specialized collaboration.
94K
$1B
38K$1B
87K$1B
102K$1B
6.9K$1B
102K$1B
74K$1B
54K$1B
8.1K$1B
15K$1B
78K$1B
36K$1B
46K$1BFibroBiologics (Nasdaq: FBLG) uses 8 technology products and services including NitroPack, Squarespace, DataTables, and more. Explore FibroBiologics (Nasdaq: FBLG)'s tech stack below.
| FibroBiologics (Nasdaq: FBLG) Email Formats | Percentage |
| First.Last@fibrobiologics.com | 50% |
| First.Last@fibrobiologics.com | 50% |
Biotechnology ResearchTexas, United States11-50 Employees
FibroBiologics (Nasdaq: FBLG) is the world leader in cell therapy using fibroblasts to regenerate tissue and cure chronic diseases. Currently, FibroBiologics holds 150+ U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, and Cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.
Company Overview
Funding & FinancialsFibroBiologics (Nasdaq: FBLG) has raised a total of $5M of funding over 2 rounds. Their latest funding round was raised on Mar 17, 2023 in the amount of $5M.
FibroBiologics (Nasdaq: FBLG)'s revenue is in the range of $10M
Funding & FinancialsFibroBiologics (Nasdaq: FBLG) has raised a total of $5M of funding over 2 rounds. Their latest funding round was raised on Mar 17, 2023 in the amount of $5M.
FibroBiologics (Nasdaq: FBLG)'s revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com